Oxaprozin loaded solid lipid nanoparticles for management of pain

Solid lipid nanoparticles (SLN) introduced in 1991 represent an alternative carrier system to tradition colloidal carriers such as emulsions, liposomes and polymeric micro and nanoparticles. Nanoparticles made from solid lipids are attracting major attention as novel colloidal drug carrier for intravenous applications as they have been proposed as an alternative particulate carrier system. SLN are sub-micron colloidal carriers ranging from 50 to 1000 nm, which are composed of physiological lipid, dispersed in water or in aqueous surfactant solution. SLN offer unique properties such as small size, large surface area, high drug loading and the interaction of phases at the interface and are attractive for their potential to improve performance of pharmaceuticals. The Solid lipid nanoparticles were successfully developed for systemic delivery of Oxaprozin. SLN dispersions were prepared by solvent injection method. Physicochemical characterization including particle size, particle size distribution, Zeta potential, scanning electron microscopy and in-vitro release profile were carried out. In-vitro drug release pattern of optimized formulation of SLN showed fast and control release.